Journal Description
Marine Drugs
Marine Drugs
is the leading, peer-reviewed, open access journal on the research, development, and production of biologically and therapeutically active compounds from the sea. Marine Drugs is published monthly online by MDPI. Australia New Zealand Marine Biotechnology Society (ANZMBS) is affiliated with Marine Drugs and its members receive a discount on article processing charges.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.
- Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 14 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the second half of 2023).
- Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
Impact Factor:
4.9 (2023);
5-Year Impact Factor:
5.2 (2023)
Latest Articles
Immunomodulatory Compounds from the Sea: From the Origins to a Modern Marine Pharmacopoeia
Mar. Drugs 2024, 22(7), 304; https://doi.org/10.3390/md22070304 (registering DOI) - 28 Jun 2024
Abstract
From sea shores to the abysses of the deep ocean, marine ecosystems have provided humanity with valuable medicinal resources. The use of marine organisms is discussed in ancient pharmacopoeias of different times and geographic regions and is still deeply rooted in traditional medicine.
[...] Read more.
From sea shores to the abysses of the deep ocean, marine ecosystems have provided humanity with valuable medicinal resources. The use of marine organisms is discussed in ancient pharmacopoeias of different times and geographic regions and is still deeply rooted in traditional medicine. Thanks to present-day, large-scale bioprospecting and rigorous screening for bioactive metabolites, the ocean is coming back as an untapped resource of natural compounds with therapeutic potential. This renewed interest in marine drugs is propelled by a burgeoning research field investigating the molecular mechanisms by which newly identified compounds intervene in the pathophysiology of human diseases. Of great clinical relevance are molecules endowed with anti-inflammatory and immunomodulatory properties with emerging applications in the management of chronic inflammatory disorders, autoimmune diseases, and cancer. Here, we review the historical development of marine pharmacology in the Eastern and Western worlds and describe the status of marine drug discovery. Finally, we discuss the importance of conducting sustainable exploitation of marine resources through biotechnology.
Full article
(This article belongs to the Special Issue Marine Immunomodulatory Compounds)
Open AccessArticle
Isolation and Total Synthesis of PM170453, a New Cyclic Depsipeptide Isolated from Lyngbya sp.
by
Rogelio Fernández, Marta Pérez, Alejandro Losada, Silvia Reboredo, Asier Gómez-San Juan, María Jesús Martín, Andrés Francesch, Simon Munt and Carmen Cuevas
Mar. Drugs 2024, 22(7), 303; https://doi.org/10.3390/md22070303 (registering DOI) - 28 Jun 2024
Abstract
In our continuing search for biologically active new chemical entities from marine organisms, we have isolated a new cyclic depsipeptide, PM170453 (1), from a cyanobacterium of the genus Lyngbya sp., collected in the Indo-Pacific Ocean. Structure elucidation of the isolated compound
[...] Read more.
In our continuing search for biologically active new chemical entities from marine organisms, we have isolated a new cyclic depsipeptide, PM170453 (1), from a cyanobacterium of the genus Lyngbya sp., collected in the Indo-Pacific Ocean. Structure elucidation of the isolated compound was determined by spectroscopic methods including MS, 1H, 13C and 2D-NMR. To solve the supply problem for 1 and progress pharmaceutical development, the total synthesis of 1 that involves a total of 20 chemical steps in a convergent process was carried out. Its in vitro cytotoxic activity against four human tumor cell lines, as well as the inhibition of the interaction between the programmed cell death protein 1 PD-1 and its ligand PD-L1 were also evaluated.
Full article
(This article belongs to the Section Synthesis and Medicinal Chemistry of Marine Natural Products)
Open AccessArticle
Streptomyces-Fungus Co-Culture Enhances the Production of Borrelidin and Analogs: A Genomic and Metabolomic Approach
by
Tan Liu, Xi Gui, Gang Zhang, Lianzhong Luo and Jing Zhao
Mar. Drugs 2024, 22(7), 302; https://doi.org/10.3390/md22070302 (registering DOI) - 28 Jun 2024
Abstract
The marine Streptomyces harbor numerous biosynthetic gene clusters (BGCs) with exploitable potential. However, many secondary metabolites cannot be produced under laboratory conditions. Co-culture strategies of marine microorganisms have yielded novel natural products with diverse biological activities. In this study, we explored the metabolic
[...] Read more.
The marine Streptomyces harbor numerous biosynthetic gene clusters (BGCs) with exploitable potential. However, many secondary metabolites cannot be produced under laboratory conditions. Co-culture strategies of marine microorganisms have yielded novel natural products with diverse biological activities. In this study, we explored the metabolic profiles of co-cultures involving Streptomyces sp. 2-85 and Cladosporium sp. 3-22—derived from marine sponges. Combining Global Natural Products Social (GNPS) Molecular Networking analysis with natural product database mining, 35 potential antimicrobial metabolites annotated were detected, 19 of which were exclusive to the co-culture, with a significant increase in production. Notably, the Streptomyces-Fungus interaction led to the increased production of borrelidin and the discovery of several analogs via molecular networking. In this study, borrelidin was first applied to combat Saprolegnia parasitica, which caused saprolegniosis in aquaculture. We noted its superior inhibitory effects on mycelial growth with an EC50 of 0.004 mg/mL and on spore germination with an EC50 of 0.005 mg/mL compared to the commercial fungicide, preliminarily identifying threonyl-tRNA synthetase as its target. Further analysis of the associated gene clusters revealed an incomplete synthesis pathway with missing malonyl-CoA units for condensation within this strain, hinting at the presence of potential compensatory pathways. In conclusion, our findings shed light on the metabolic changes of marine Streptomyces and fungi in co-culture, propose the potential of borrelidin in the control of aquatic diseases, and present new prospects for antifungal applications.
Full article
(This article belongs to the Special Issue Genome Mining and Drug Discovery of Marine and Halophilic Microorganisms)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00302/article_deploy/marinedrugs-22-00302-ag.jpg?1719587724)
Graphical abstract
Open AccessReview
Marine-Derived Lipases for Enhancing Enrichment of Very-Long-Chain Polyunsaturated Fatty Acids with Reference to Omega-3 Fatty Acids
by
Mahejbin Karia, Mona Kaspal, Mariam Alhattab and Munish Puri
Mar. Drugs 2024, 22(7), 301; https://doi.org/10.3390/md22070301 (registering DOI) - 28 Jun 2024
Abstract
Omega-3 fatty acids are essential fatty acids that are not synthesised by the human body and have been linked with the prevention of chronic illnesses such as cardiovascular and neurodegenerative diseases. However, the current dietary habits of the majority of the population include
[...] Read more.
Omega-3 fatty acids are essential fatty acids that are not synthesised by the human body and have been linked with the prevention of chronic illnesses such as cardiovascular and neurodegenerative diseases. However, the current dietary habits of the majority of the population include lower omega-3 content compared to omega-6, which does not promote good health. To overcome this, pharmaceutical and nutraceutical companies aim to produce omega-3-fortified foods. For this purpose, various approaches have been employed to obtain omega-3 concentrates from sources such as fish and algal oil with higher amounts of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Among these techniques, enzymatic enrichment using lipase enzymes has gained tremendous interest as it is low in capital cost and simple in operation. Microorganism-derived lipases are preferred as they are easily produced due to their higher growth rate, and they hold the ability to be manipulated using genetic modification. This review aims to highlight the recent studies that have been carried out using marine lipases for the enrichment of omega-3, to provide insight into future directions. Overall, the covalent bond-based lipase immobilization to various support materials appears most promising; however, greener and less expensive options need to be strengthened.
Full article
(This article belongs to the Special Issue Biotechnological Applications of Marine Enzymes)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00301/article_deploy/html/images/marinedrugs-22-00301-g001-550.jpg?1719572549)
Figure 1
Open AccessArticle
Posidonia oceanica (L.) Delile is a Promising Marine Source Able to Alleviate Imiquimod-Induced Psoriatic Skin Inflammation
by
Micheli Laura, Vasarri Marzia, Degl’Innocenti Donatella, Di Cesare Mannelli Lorenzo, Ghelardini Carla, Antiga Emiliano, Verdelli Alice, Caproni Marzia and Barletta Emanuela
Mar. Drugs 2024, 22(7), 300; https://doi.org/10.3390/md22070300 - 28 Jun 2024
Abstract
Psoriasis is a chronic immune-mediated inflammatory cutaneous disease characterized by elevated levels of inflammatory cytokines and adipokine Lipocalin-2 (LCN-2). Recently, natural plant-based products have been studied as new antipsoriatic compounds. We investigate the ability of a leaf extract of the marine plant Posidonia
[...] Read more.
Psoriasis is a chronic immune-mediated inflammatory cutaneous disease characterized by elevated levels of inflammatory cytokines and adipokine Lipocalin-2 (LCN-2). Recently, natural plant-based products have been studied as new antipsoriatic compounds. We investigate the ability of a leaf extract of the marine plant Posidonia oceanica (POE) to inhibit psoriatic dermatitis in C57BL/6 mice treated with Imiquimod (IMQ). One group of mice was topically treated with IMQ (IMQ mice) for 5 days, and a second group received POE orally before each topical IMQ treatment (IMQ-POE mice). Psoriasis Area Severity Index (PASI) score, thickness, and temperature of the skin area treated with IMQ were measured in both groups. Upon sacrifice, the organs were weighed, and skin biopsies and blood samples were collected. Plasma and lesional skin protein expression of IL-17, IL-23, IF-g, IL-2, and TNF-α and plasma LCN-2 concentration were evaluated by ELISA. PASI score, thickness, and temperature of lesional skin were reduced in IMQ-POE mice, as were histological features of psoriatic dermatitis and expression of inflammatory cytokines and LCN-2 levels. This preliminary study aims to propose P. oceanica as a promising naturopathic anti-inflammatory treatment that could be introduced in Complementary Medicine for psoriasis.
Full article
(This article belongs to the Special Issue Marine Anti-inflammatory and Antioxidant Agents 3.0)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00300/article_deploy/html/images/marinedrugs-22-00300-g001-550.jpg?1719565541)
Figure 1
Open AccessReview
Whole-Cell Biosensor for Iron Monitoring as a Potential Tool for Safeguarding Biodiversity in Polar Marine Environments
by
Marzia Calvanese, Caterina D’Angelo, Maria Luisa Tutino and Concetta Lauro
Mar. Drugs 2024, 22(7), 299; https://doi.org/10.3390/md22070299 - 28 Jun 2024
Abstract
Iron is a key micronutrient essential for various essential biological processes. As a consequence, alteration in iron concentration in seawater can deeply influence marine biodiversity. In polar marine environments, where environmental conditions are characterized by low temperatures, the role of iron becomes particularly
[...] Read more.
Iron is a key micronutrient essential for various essential biological processes. As a consequence, alteration in iron concentration in seawater can deeply influence marine biodiversity. In polar marine environments, where environmental conditions are characterized by low temperatures, the role of iron becomes particularly significant. While iron limitation can negatively influence primary production and nutrient cycling, excessive iron concentrations can lead to harmful algal blooms and oxygen depletion. Furthermore, the growth of certain phytoplankton species can be increased in high-iron-content environments, resulting in altered balance in the marine food web and reduced biodiversity. Although many chemical/physical methods are established for inorganic iron quantification, the determination of the bio-available iron in seawater samples is more suitably carried out using marine microorganisms as biosensors. Despite existing challenges, whole-cell biosensors offer other advantages, such as real-time detection, cost-effectiveness, and ease of manipulation, making them promising tools for monitoring environmental iron levels in polar marine ecosystems. In this review, we discuss fundamental biosensor designs and assemblies, arranging host features, transcription factors, reporter proteins, and detection methods. The progress in the genetic manipulation of iron-responsive regulatory and reporter modules is also addressed to the optimization of the biosensor performance, focusing on the improvement of sensitivity and specificity.
Full article
(This article belongs to the Special Issue Polar Marine Bacteria: From Physiology to Biotechnological Applications)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00299/article_deploy/html/images/marinedrugs-22-00299-g001-550.jpg?1719562052)
Figure 1
Open AccessArticle
Identification of Axinellamines A and B as Anti-Tubercular Agents
by
Emily J. Strong, Lendl Tan, Sasha Hayes, Hayden Whyte, Rohan A. Davis and Nicholas P. West
Mar. Drugs 2024, 22(7), 298; https://doi.org/10.3390/md22070298 - 28 Jun 2024
Abstract
Tuberculosis remains a significant global health pandemic. There is an urgent need for new anti-tubercular agents to combat the rising incidence of drug resistance and to offer effective and additive therapeutic options. High-throughput screening of a subset of the NatureBank marine fraction library
[...] Read more.
Tuberculosis remains a significant global health pandemic. There is an urgent need for new anti-tubercular agents to combat the rising incidence of drug resistance and to offer effective and additive therapeutic options. High-throughput screening of a subset of the NatureBank marine fraction library (n = 2000) identified a sample derived from an Australian marine sponge belonging to the order Haplosclerida that displayed promising anti-mycobacterial activity. Bioassay-guided fractionation of the organic extract from this Haplosclerida sponge led to the purification of previously identified antimicrobial pyrrole alkaloids, axinellamines A (1) and B (2). The axinellamine compounds were found to have a 90% minimum inhibitory concentration (MIC90) of 18 µM and 15 µM, respectively. The removal of protein and complex carbon sources reduced the MIC90 of 1 and 2 to 0.6 and 0.8 µM, respectively. The axinellamines were not toxic to mammalian cells at 25 µM and significantly reduced the intracellular bacterial load by >5-fold. These data demonstrate that axinellamines A and B are effective anti-tubercular agents and promising targets for future medicinal chemistry efforts.
Full article
(This article belongs to the Special Issue Bio-Active Components from Marine Sponges)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00298/article_deploy/html/images/marinedrugs-22-00298-g001-550.jpg?1719553667)
Figure 1
Open AccessArticle
Generation, Characterisation and Identification of Bioactive Peptides from Mesopelagic Fish Protein Hydrolysates Using In Silico and In Vitro Approaches
by
Maria Hayes, Azza Naik, Leticia Mora, Bruno Iñarra, Jone Ibarruri, Carlos Bald, Thibault Cariou, David Reid, Michael Gallagher, Ragnhild Dragøy, Jorge Galino, Alba Deyà, Sissel Albrektsen, Lars Thoresen and Runar G. Solstad
Mar. Drugs 2024, 22(7), 297; https://doi.org/10.3390/md22070297 - 27 Jun 2024
Abstract
This study generated bioactive hydrolysates using the enzyme Alcalase and autolysis from mesopelagic fish, including Maurolicus muelleri and Benthosema glaciale. Generated hydrolysates were investigated for their bioactivities using in vitro bioassays, and bioactive peptides were identified using mass spectrometry in active hydrolysates
[...] Read more.
This study generated bioactive hydrolysates using the enzyme Alcalase and autolysis from mesopelagic fish, including Maurolicus muelleri and Benthosema glaciale. Generated hydrolysates were investigated for their bioactivities using in vitro bioassays, and bioactive peptides were identified using mass spectrometry in active hydrolysates with cyclooxygenase, dipeptidyl peptidase IV and antioxidant activities. In silico analysis was employed to rank identified peptide sequences in terms of overall bioactivity using programmes including Peptide Ranker, PrepAIP, Umami-MRNN and AntiDMPpred. Seven peptides predicted to have anti-inflammatory, anti-type 2 diabetes or Umami potential using in silico strategies were chemically synthesised, and their anti-inflammatory activities were confirmed using in vitro bioassays with COX-1 and COX-2 enzymes. The peptide QCPLHRPWAL inhibited COX-1 and COX-2 by 82.90% (+/−0.54) and 53.84%, respectively, and had a selectivity index greater than 10. This peptide warrants further research as a novel anti-inflammatory/pain relief peptide. Other peptides with DPP-IV inhibitory and Umami flavours were identified. These offer potential for use as functional foods or topical agents to prevent pain and inflammation.
Full article
(This article belongs to the Special Issue Bioactive Compounds from Marine Fish)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00297/article_deploy/html/images/marinedrugs-22-00297-g001-550.jpg?1719565435)
Figure 1
Open AccessArticle
Discovery of Prenyltransferase-Guided Hydroxyphenylacetic Acid Derivatives from Marine Fungus Penicillium sp. W21C371
by
Cancan Wang, Ye Fan, Chenjie Wang, Jing Tang, Yixian Qiu, Keren Xu, Yingjia Ding, Ying Liu, Youmin Ying and Hong Wang
Mar. Drugs 2024, 22(7), 296; https://doi.org/10.3390/md22070296 - 26 Jun 2024
Abstract
Traditional isolation methods often lead to the rediscovery of known natural products. In contrast, genome mining strategies are considered effective for the continual discovery of new natural products. In this study, we discovered a unique prenyltransferase (PT) through genome mining, capable of catalyzing
[...] Read more.
Traditional isolation methods often lead to the rediscovery of known natural products. In contrast, genome mining strategies are considered effective for the continual discovery of new natural products. In this study, we discovered a unique prenyltransferase (PT) through genome mining, capable of catalyzing the transfer of a prenyl group to an aromatic nucleus to form C-C or C-O bonds. A pair of new hydroxyphenylacetic acid derivative enantiomers with prenyl units, (±)-peniprenydiol A (1), along with 16 known compounds (2–17), were isolated from a marine fungus, Penicillium sp. W21C371. The separation of 1 using chiral HPLC led to the isolation of the enantiomers 1a and 1b. Their structures were established on the basis of extensive spectroscopic analysis, including 1D, 2D NMR and HRESIMS. The absolute configurations of the new compounds were determined by a modified Mosher method. A plausible biosynthetic pathway for 1 was deduced, facilitated by PT catalysis. In the in vitro assay, 2 and 3 showed promising inhibitory activity against Escherichia coli β-glucuronidase (EcGUS), with IC50 values of 44.60 ± 0.84 μM and 21.60 ± 0.76 μM, respectively, compared to the positive control, D-saccharic acid 1,4-lactone hydrate (DSL). This study demonstrates the advantages of genome mining in the rational acquisition of new natural products.
Full article
(This article belongs to the Special Issue Discovery of Marine Natural Products in China: Selected Papers from the 16th National Annual Conference and 2023 International Symposium on Marine Drugs (16-NASMD) Conference)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00296/article_deploy/html/images/marinedrugs-22-00296-g001-550.jpg?1719408197)
Figure 1
Open AccessArticle
A Marine Collagen-Based 3D Scaffold for In Vitro Modeling of Human Prostate Cancer Niche and Anti-Cancer Therapeutic Discovery
by
Won Hoon Song, Ye Seon Lim, Ji-Eun Kim, Hae Yeong Kang, Changyong Lee, Lata Rajbongshi, Seon Yeong Hwang, Sae-Ock Oh, Byoung Soo Kim, Dongjun Lee, Yong Jung Song and Sik Yoon
Mar. Drugs 2024, 22(7), 295; https://doi.org/10.3390/md22070295 - 26 Jun 2024
Abstract
Recently, the need to develop a robust three-dimensional (3D) cell culture system that serves as a valuable in vitro tumor model has been emphasized. This system should closely mimic the tumor growth behaviors observed in vivo and replicate the key elements and characteristics
[...] Read more.
Recently, the need to develop a robust three-dimensional (3D) cell culture system that serves as a valuable in vitro tumor model has been emphasized. This system should closely mimic the tumor growth behaviors observed in vivo and replicate the key elements and characteristics of human tumors for the effective discovery and development of anti-tumor therapeutics. Therefore, in this study, we developed an effective 3D in vitro model of human prostate cancer (PC) using a marine collagen-based biomimetic 3D scaffold. The model displayed distinctive molecular profiles and cellular properties compared with those of the 2D PC cell culture. This was evidenced by (1) increased cell proliferation, migration, invasion, colony formation, and chemoresistance; (2) upregulated expression of crucial multidrug-resistance- and cancer-stemness-related genes; (3) heightened expression of key molecules associated with malignant progressions, such as epithelial–mesenchymal transition transcription factors, Notch, matrix metalloproteinases, and pluripotency biomarkers; (4) robust enrichment of prostate cancer stem cells (CSCs); and (5) enhanced expression of integrins. These results suggest that our 3D in vitro PC model has the potential to serve as a research platform for studying PC and prostate CSC biology, as well as for screening novel therapies targeting PC and prostate CSCs.
Full article
(This article belongs to the Special Issue Fundamentals and Biomedical Applications of Marine Collagen)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00295/article_deploy/html/images/marinedrugs-22-00295-g001-550.jpg?1719407290)
Figure 1
Open AccessArticle
Sulfated Polyhydroxysteroid Glycosides from the Sea of Okhotsk Starfish Henricia leviuscula spiculifera and Potential Mechanisms for Their Observed Anti-Cancer Activity against Several Types of Human Cancer Cells
by
Alla A. Kicha, Dmitriy K. Tolkanov, Timofey V. Malyarenko, Olesya S. Malyarenko, Alexandra S. Kuzmich, Anatoly I. Kalinovsky, Roman S. Popov, Valentin A. Stonik, Natalia V. Ivanchina and Pavel S. Dmitrenok
Mar. Drugs 2024, 22(7), 294; https://doi.org/10.3390/md22070294 - 26 Jun 2024
Abstract
Three new monosulfated polyhydroxysteroid glycosides, spiculiferosides A (1), B (2), and C (3), along with new related unsulfated monoglycoside, spiculiferoside D (4), were isolated from an ethanolic extract of the starfish Henricia leviuscula spiculifera collected
[...] Read more.
Three new monosulfated polyhydroxysteroid glycosides, spiculiferosides A (1), B (2), and C (3), along with new related unsulfated monoglycoside, spiculiferoside D (4), were isolated from an ethanolic extract of the starfish Henricia leviuscula spiculifera collected in the Sea of Okhotsk. Compounds 1–3 contain two carbohydrate moieties, one of which is attached to C-3 of the steroid tetracyclic core, whereas another is located at C-24 of the side chain of aglycon. Two glycosides (2, 3) are biosides, and one glycoside (1), unlike them, includes three monosaccharide residues. Such type triosides are a rare group of polar steroids of sea stars. In addition, the 5-substituted 3-OSO3-α-L-Araf unit was found in steroid glycosides from starfish for the first time. Cell viability analysis showed that 1–3 (at concentrations up to 100 μM) had negligible cytotoxicity against human embryonic kidney HEK293, melanoma SK-MEL-28, breast cancer MDA-MB-231, and colorectal carcinoma HCT 116 cells. These compounds significantly inhibited proliferation and colony formation in HCT 116 cells at non-toxic concentrations, with compound 3 having the greatest effect. Compound 3 exerted anti-proliferative effects on HCT 116 cells through the induction of dose-dependent cell cycle arrest at the G2/M phase, regulation of expression of cell cycle proteins CDK2, CDK4, cyclin D1, p21, and inhibition of phosphorylation of protein kinases c-Raf, MEK1/2, ERK1/2 of the MAPK/ERK1/2 pathway.
Full article
(This article belongs to the Special Issue Marine Glycomics 2nd Edition)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00294/article_deploy/html/images/marinedrugs-22-00294-ag-550.jpg?1719400594)
Graphical abstract
Open AccessArticle
Tunicamycins from Marine-Derived Streptomyces bacillaris Inhibit MurNAc-Pentapeptide Translocase in Staphylococcus aureus
by
Jayho Lee, Ji-Yeon Hwang, Daehyun Oh, Dong-Chan Oh, Hyeung-geun Park, Jongheon Shin and Ki-Bong Oh
Mar. Drugs 2024, 22(7), 293; https://doi.org/10.3390/md22070293 - 26 Jun 2024
Abstract
Four tunicamycin class compounds, tunicamycin VII (1), tunicamycin VIII (2), corynetoxin U17a (3), and tunicamycin IX (4), were isolated from the culture broth of the marine-derived actinomycete Streptomyces sp. MBTG32. The strain was identified using
[...] Read more.
Four tunicamycin class compounds, tunicamycin VII (1), tunicamycin VIII (2), corynetoxin U17a (3), and tunicamycin IX (4), were isolated from the culture broth of the marine-derived actinomycete Streptomyces sp. MBTG32. The strain was identified using the 16S rDNA sequencing technique, and the isolated strain was closely related to Streptomyces bacillaris. The structures of the isolated compounds were elucidated based on spectroscopic data and comparisons with previously reported NMR data. Compounds 1–4 showed potent antibacterial activities against Gram-positive bacteria, especially Staphylococcus aureus, with MIC values of 0.13–0.25 µg/mL. Through a recombinant enzyme assay and overexpression analysis, we found that the isolated compounds exerted potent inhibitory effects on S. aureus MurNAc-pentapeptide translocase (MraY), with IC50 values of 0.08–0.21 µg/mL. The present results support that the underlying mechanism of action of tunicamycins isolated from marine-derived Streptomyces sp. is also associated with the inhibition of MraY enzyme activity in S. aureus.
Full article
(This article belongs to the Section Marine Pharmacology)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00293/article_deploy/html/images/marinedrugs-22-00293-g001-550.jpg?1719398344)
Figure 1
Open AccessArticle
The Composition of Triterpene Glycosides in the Sea Cucumber Psolus peronii: Anticancer Activity of the Glycosides against Three Human Breast Cancer Cell Lines and Quantitative Structure–Activity Relationships (QSAR)
by
Alexandra Sergeevna Silchenko, Anatoly Ivanovich Kalinovsky, Sergey Anatolievich Avilov, Roman Sergeevich Popov, Ekaterina Alexandrovna Chingizova, Ekaterina Sergeevna Menchinskaya, Elena Alexandrovna Zelepuga, Kseniya Mikhailovna Tabakmakher, Vadim Georgievich Stepanov and Vladimir Ivanovich Kalinin
Mar. Drugs 2024, 22(7), 292; https://doi.org/10.3390/md22070292 - 26 Jun 2024
Abstract
Eight sulfated triterpene glycosides, peronioside A (1) and psolusosides A (2), B (3), G (4), I (5), L (6), N (7) and P (8), were isolated from
[...] Read more.
Eight sulfated triterpene glycosides, peronioside A (1) and psolusosides A (2), B (3), G (4), I (5), L (6), N (7) and P (8), were isolated from the sea cucumber Psolus peronii. Peronioside A (1) is a new glycoside, while compounds 2–8 were found previously in Psolus fabricii, indicating the phylogenetic and systematic closeness of these species of sea cucumbers. The activity of 1–8 against human erythrocytes and their cytotoxicity against the breast cancer cell lines MCF-7, T-47D and triple-negative MDA-MB-231 were tested. The most active against cancer cell compounds, psolusosides A (2) and L (6), which were not cytotoxic to the non-transformed cells of the mammary gland, were chosen to study the inhibition of the migration, formation and growth of colonies of the cancer cell lines. Glycoside 2 effectively inhibited the growth of colonies and the migration of the MDA-MB-231 cell line. Compound 6 blocked the growth of colonies of T-47D cells and showed a pronounced antimigration effect on MDA-MB-231 cells. The quantitative structure–activity relationships (QSAR) indicated the strong impact on the activity of the form and size of the molecules, which is connected to the length and architecture of the carbohydrate chain, the distribution of charge on the molecules’ surface and various aspects of hydrogen bond formation, depending on the quantity and positions of the sulfate groups. The QSAR calculations were in good accordance with the observed SAR tendencies.
Full article
(This article belongs to the Section Marine Pharmacology)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00292/article_deploy/html/images/marinedrugs-22-00292-ag-550.jpg?1719487735)
Graphical abstract
Open AccessReview
Proof of Concept of Natural and Synthetic Antifouling Agents in Coatings
by
Daniela Pereira, Joana R. Almeida, Honorina Cidade and Marta Correia-da-Silva
Mar. Drugs 2024, 22(7), 291; https://doi.org/10.3390/md22070291 - 24 Jun 2024
Abstract
Marine biofouling, caused by the deposition and accumulation of marine organisms on submerged surfaces, represents a huge concern for the maritime industries and also contributes to environmental pollution and health concerns. The most effective way to prevent this phenomenon is the use of
[...] Read more.
Marine biofouling, caused by the deposition and accumulation of marine organisms on submerged surfaces, represents a huge concern for the maritime industries and also contributes to environmental pollution and health concerns. The most effective way to prevent this phenomenon is the use of biocide-based coatings which have proven to cause serious damage to marine ecosystems. Several research groups have focused on the search for new environmentally friendly antifoulants, including marine and terrestrial natural products and synthetic analogues. Some of these compounds have been incorporated into marine coatings and display interesting antifouling activities caused by the interference with the biofilm-forming species as well as by the inhibition of the settlement of macroorganisms. This review highlights the proof-of-concept studies of emerging natural or synthetic antifouling compounds in coatings, from lab-made to commercial ones, performed between 2019 and 2023 and their results in the field or in in vivo laboratorial tests.
Full article
(This article belongs to the Special Issue Marine Anti-biofilm Compounds from Natural to Synthetic Compounds)
Open AccessSystematic Review
Fucoidan as a Promising Drug for Pain Treatment: Systematic Review and Meta-Analysis
by
Miguel Á. Huerta, Miguel Á. Tejada and Francisco R. Nieto
Mar. Drugs 2024, 22(7), 290; https://doi.org/10.3390/md22070290 - 24 Jun 2024
Abstract
Fucoidan is a polymer of L-fucose and L-fucose-4-sulphate naturally found in marine sources that inhibits p-selectin, preventing neutrophil recruitment to the site of injury. Fucoidan is employed in many studies as a tool to investigate the contribution of neutrophils to pain, showing analgesic
[...] Read more.
Fucoidan is a polymer of L-fucose and L-fucose-4-sulphate naturally found in marine sources that inhibits p-selectin, preventing neutrophil recruitment to the site of injury. Fucoidan is employed in many studies as a tool to investigate the contribution of neutrophils to pain, showing analgesic effects. We performed a systematic review and meta-analysis to quantify the analgesic effects of pretreatment with fucoidan reported in the available preclinical studies. In addition, we summarized the articles which have studied the therapeutic effects of fucoidan in pathological pain at preclinical and clinical levels. The results of this systematic review reveal that pretreatment with fucoidan is a powerful tool which reduces neutrophil infiltration by 70–90% at early time points. This meta-analysis showed that preventative treatment with fucoidan produced a significant pain reduction. In addition, several preclinical studies have observed that fucoidan treatment reduces the pain that is associated with various pathologies. Finally, fucoidan has also been tested in several clinical trials, with some degree of analgesic efficacy, but they were mostly small pilot studies. Considering all the above information, it can be concluded that fucoidan is not only a preclinical tool for studying the role of neutrophils in pain but also a promising therapeutic strategy for pain treatment.
Full article
(This article belongs to the Section Marine Pharmacology)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00290/article_deploy/html/images/marinedrugs-22-00290-g001-550.jpg?1719227478)
Figure 1
Open AccessArticle
Genomic Analysis of Novel Sulfitobacter Bacterial Strains Isolated from Marine Biofilms
by
Han Cui, Shen Fan, Wei Ding and Weipeng Zhang
Mar. Drugs 2024, 22(7), 289; https://doi.org/10.3390/md22070289 - 22 Jun 2024
Abstract
Bacteria from the genus Sulfitobacter are distributed across various marine habitats and play a significant role in sulfur cycling. However, the metabolic features of Sulfitobacter inhabiting marine biofilms are still not well understood. Here, complete genomes and paired metatranscriptomes of eight Sulfitobacter strains,
[...] Read more.
Bacteria from the genus Sulfitobacter are distributed across various marine habitats and play a significant role in sulfur cycling. However, the metabolic features of Sulfitobacter inhabiting marine biofilms are still not well understood. Here, complete genomes and paired metatranscriptomes of eight Sulfitobacter strains, isolated from biofilms on subtidal stones, have been analyzed to explore their central energy metabolism and potential of secondary metabolite biosynthesis. Based on average nucleotide identity and phylogenetic analysis, the eight strains were classified into six novel species and two novel strains. The reconstruction of the metabolic pathways indicated that all strains had a complete Entner–Doudoroff pathway, pentose phosphate pathway, and diverse pathways for amino acid metabolism, suggesting the presence of an optimized central carbon metabolism. Pangenome analysis further revealed the differences between the gene cluster distribution patterns among the eight strains, suggesting significant functional variation. Moreover, a total of 47 biosynthetic gene clusters were discovered, which were further classified into 37 gene cluster families that showed low similarity with previously documented clusters. Furthermore, metatranscriptomic analysis revealed the expressions of key functional genes involved in the biosynthesis of ribosomal peptides in in situ marine biofilms. Overall, this study sheds new light on the metabolic features, adaptive strategies, and value of genome mining in this group of biofilm-associated Sulfitobacter bacteria.
Full article
(This article belongs to the Special Issue Biosynthesis of Marine Microbial Natural Products)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00289/article_deploy/html/images/marinedrugs-22-00289-g001-550.jpg?1719051292)
Figure 1
Open AccessReview
Effects of Marine Natural Products on Liver Diseases
by
Yandi Sun, Yansong Dong, Xiaohang Cui, Xiaohe Guo, Juan Zhang, Chong Yu, Man Zhang and Haifeng Wang
Mar. Drugs 2024, 22(7), 288; https://doi.org/10.3390/md22070288 - 21 Jun 2024
Abstract
The prevention and treatment of liver disease, a class of disease that seriously threatens human health, has always been a hot topic of medical research. In recent years, with the in-depth exploration of marine resources, marine natural products have shown great potential and
[...] Read more.
The prevention and treatment of liver disease, a class of disease that seriously threatens human health, has always been a hot topic of medical research. In recent years, with the in-depth exploration of marine resources, marine natural products have shown great potential and value in the field of liver disease treatment. Compounds extracted and isolated from marine natural products have a variety of biological activities such as significant antiviral properties, showing potential in the management of alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD), protection of the liver from fibrosis, protection from liver injury and inhibition of the growth of hepatocellular carcinoma (HCC). This paper summarizes the progress of research on marine natural products for the treatment of liver diseases in the past decade, including the structural types of active substances from different natural products and the mechanisms underlying the modulation of different liver diseases and reviews their future prospects.
Full article
(This article belongs to the Section Marine Pharmacology)
Open AccessArticle
Heterologous Expression and Characterization of a pH-Stable Chitinase from Micromonospora aurantiaca with a Potential Application in Chitin Degradation
by
Han-Zhong Guo, Dou Wang, Hui-Ting Yang, Yu-Le Wu, Yong-Cheng Li, Guang-Hua Xia and Xue-Ying Zhang
Mar. Drugs 2024, 22(6), 287; https://doi.org/10.3390/md22060287 - 20 Jun 2024
Abstract
To promote the bioconversion of marine chitin waste into value-added products, we expressed a novel pH-stable Micromonospora aurantiaca-derived chitinase, MaChi1, in Escherichia coli and subsequently purified, characterized, and evaluated it for its chitin-converting capacity. Our results indicated that MaChi1 is
[...] Read more.
To promote the bioconversion of marine chitin waste into value-added products, we expressed a novel pH-stable Micromonospora aurantiaca-derived chitinase, MaChi1, in Escherichia coli and subsequently purified, characterized, and evaluated it for its chitin-converting capacity. Our results indicated that MaChi1 is of the glycoside hydrolase (GH) family 18 with a molecular weight of approximately 57 kDa, consisting of a GH18 catalytic domain and a cellulose-binding domain. We recorded its optimal activity at pH 5.0 and 55 °C. It exhibited excellent stability in a wide pH range of 3.0–10.0. Mg2+ (5 mM), and dithiothreitol (10 mM) significantly promoted MaChi1 activity. MaChi1 exhibited broad substrate specificity and hydrolyzed chitin, chitosan, cellulose, soluble starch, and N-acetyl chitooligosaccharides with polymerization degrees ranging from three to six. Moreover, MaChi1 exhibited an endo-type cleavage pattern, and it could efficiently convert colloidal chitin into N-acetyl-D-glucosamine (GlcNAc) and (GlcNAc)2 with yields of 227.2 and 505.9 mg/g chitin, respectively. Its high chitin-degrading capacity and exceptional pH tolerance makes it a promising tool with potential applications in chitin waste treatment and bioactive oligosaccharide production.
Full article
(This article belongs to the Section Biomaterials of Marine Origin)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00287/article_deploy/html/images/marinedrugs-22-00287-ag-550.jpg?1719293251)
Graphical abstract
Open AccessArticle
A Tripeptide (Ser-Arg-Pro, SRP) from Sipunculus nudus L. Improves Cadmium-Induced Acute Kidney Injury by Targeting the MAPK, Inflammatory, and Apoptosis Pathways in Mice
by
Yanmei Pan, Zhilan Peng, Zhijia Fang, Lukman Iddrisu, Lijun Sun, Qi Deng and Ravi Gooneratne
Mar. Drugs 2024, 22(6), 286; https://doi.org/10.3390/md22060286 - 20 Jun 2024
Abstract
Cadmium (Cd) is a toxic heavy metal that causes nephrosis, including acute kidney injury. To prevent and treat acute kidney injury (AKI) following Cd exposure, a tripeptide, Ser-Arg-Pro (SRP), from Sipunculus nudus L. was employed, and its potential efficacy in AKI was assessed.
[...] Read more.
Cadmium (Cd) is a toxic heavy metal that causes nephrosis, including acute kidney injury. To prevent and treat acute kidney injury (AKI) following Cd exposure, a tripeptide, Ser-Arg-Pro (SRP), from Sipunculus nudus L. was employed, and its potential efficacy in AKI was assessed. Oral administration of SRP significantly alleviated Cd-induced kidney damage, leading to improved renal function and the attenuation of structural abnormalities. A network pharmacology analysis revealed the potential of SRP in renal protection by targeting various pathways, including mitogen-activated protein kinase (MAPK) signaling, inflammatory response, and apoptosis pathways. Mechanistic studies indicated that SRP achieves renal protection by inhibiting the activation of MAPK pathways (phosphorylation of p38, p56, ERK, and JNK) in the oxidative stress cascade, suppressing inflammatory responses (iNOS, Arg1, Cox2, TNF-α, IL-1β, and IL-6), and restoring altered apoptosis factors (caspase-9, caspase-3, Bax, and Bcl-2). Hence, SRP has the potential to be used as a therapeutic agent for the treatment of Cd-induced nephrotoxicity.
Full article
(This article belongs to the Special Issue Marine Alkaloids: Sources, Discovery, Diversity, and Bioactivities)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00286/article_deploy/html/images/marinedrugs-22-00286-g001-550.jpg?1718877498)
Figure 1
Open AccessArticle
Reversed-Phase Medium-Pressure Liquid Chromatography Purification of Omega-3 Fatty Acid Ethyl Esters Using AQ-C18
by
Mingxin Sang, Nan Pan, Jingna Wu, Xiaoting Chen, Shuilin Cai, Huan Fang, Meitian Xiao, Xiaoming Jiang and Zhiyu Liu
Mar. Drugs 2024, 22(6), 285; https://doi.org/10.3390/md22060285 - 19 Jun 2024
Abstract
Omega-3 fatty acids are in high demand due to their efficacy in treating hypertriglyceridemia and preventing cardiovascular diseases. However, the growth of the industry is hampered by low purity and insufficient productivity. This study aims to develop an efficient RP-MPLC purification method for
[...] Read more.
Omega-3 fatty acids are in high demand due to their efficacy in treating hypertriglyceridemia and preventing cardiovascular diseases. However, the growth of the industry is hampered by low purity and insufficient productivity. This study aims to develop an efficient RP-MPLC purification method for omega-3 fatty acid ethyl esters with high purity and capacity. The results indicate that the AQ-C18 featuring polar end-capped silanol groups outperformed C18 and others in retention time and impurity separation. By injecting pure fish oil esters with a volume equivalent to a 1.25% bed volume on an AQ-C18 MPLC column using a binary isocratic methanol–water (90:10, v:v) mobile phase at 30 mL/min, optimal omega-3 fatty acid ethyl esters were obtained, with the notable purity of 90.34% and a recovery rate of 74.30%. The total content of EPA and DHA produced increased from 67.91% to 85.27%, meeting the acceptance criteria of no less than 84% set by the 2020 edition of the Pharmacopoeia of the People’s Republic of China. In contrast, RP-MPLC significantly enhanced the production efficiency per unit output compared to RP-HPLC. This study demonstrates a pioneering approach to producing omega-3 fatty acid ethyl esters with high purity and of greater quantity using AQ-C18 RP-MPLC, showing this method’s significant potential for use in industrial-scale manufacturing.
Full article
(This article belongs to the Special Issue Fatty Acids from Marine Organisms, 2nd Edition)
►▼
Show Figures
![](https://pub.mdpi-res.com/marinedrugs/marinedrugs-22-00285/article_deploy/html/images/marinedrugs-22-00285-g001-550.jpg?1718775597)
Figure 1
![Marine Drugs marinedrugs-logo](https://pub.mdpi-res.com/img/journals/marinedrugs-logo.png?8600e93ff98dbf14)
Journal Menu
► ▼ Journal Menu-
- Marine Drugs Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Vol. 22 (2024)
- Vol. 21 (2023)
- Vol. 20 (2022)
- Vol. 19 (2021)
- Vol. 18 (2020)
- Vol. 17 (2019)
- Vol. 16 (2018)
- Vol. 15 (2017)
- Vol. 14 (2016)
- Vol. 13 (2015)
- Vol. 12 (2014)
- Vol. 11 (2013)
- Vol. 10 (2012)
- Vol. 9 (2011)
- Vol. 8 (2010)
- Vol. 7 (2009)
- Vol. 6 (2008)
- Vol. 5 (2007)
- Vol. 4 (2006)
- Vol. 3 (2005)
- Vol. 2 (2004)
- Vol. 1 (2003)
Highly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Applied Biosciences, JMSE, Marine Drugs, Toxins, Molecules
Marine Biotoxins and Bioactive Marine Natural Products
Topic Editors: Naomasa Oshiro, Ana Gago-Martínez, Takeshi Tsumuraya, Tsuyoshi IkeharaDeadline: 31 August 2024
Topic in
Molecules, Pharmaceutics, Antibiotics, Microorganisms, Biomolecules, Marine Drugs, Polymers, IJMS
Antimicrobial Agents and Nanomaterials
Topic Editors: Sandra Pinto, Vasco D. B. BonifácioDeadline: 30 September 2024
Topic in
Biomolecules, IJMS, Molecules, Sci. Pharm., Marine Drugs, Plants
Antioxidant Activity of Natural Products—2nd Edition
Topic Editors: José Virgílio Santulhão Pinela, Maria Inês Moreira Figueiredo Dias, Carla Susana Correia Pereira, Alexandra PlácidoDeadline: 30 September 2025
![loading...](https://pub.mdpi-res.com/img/loading_circle.gif?9a82694213036313?1719563568)
Conferences
Special Issues
Special Issue in
Marine Drugs
Challenges on Structural Determination of Marine Natural Products
Guest Editors: Bae Munhyung, Jae-hyuk JangDeadline: 30 June 2024
Special Issue in
Marine Drugs
Bioactive Polysaccharides from Seaweeds
Guest Editors: Faiez Hentati, Laurent VandanjonDeadline: 31 July 2024
Special Issue in
Marine Drugs
Sustainable Circular Bioeconomy Approaches for the Biotechnological Development of Marine-Derived Products
Guest Editors: Susana P. Gaudencio, Ana Rotter, Cristiana A. V. TorresDeadline: 31 August 2024
Special Issue in
Marine Drugs
Value-Added Products from Marine Fishes
Guest Editors: Helena Maria Lourenço, Sónia PedroDeadline: 15 September 2024
Topical Collections
Topical Collection in
Marine Drugs
Microalgal Active Biomolecules
Collection Editor: Cédric Delattre
Topical Collection in
Marine Drugs
Marine Compounds and Cancer
Collection Editors: Friedemann Honecker, Sergey A. Dyshlovoy
Topical Collection in
Marine Drugs
Papers from “Sino–Italian Symposium on Bioactive Natural Products”
Collection Editors: Orazio Taglialatela-Scafati, Hong Wang